Abstract
Twenty-five years ago the first small molecule inhibitors of Hsp90 were identified. In the intervening years there has been dramatic progress in basic scientific understanding of the Hsp90 chaperone machinery and in the role of Hsp90 in malignancy. The first-in-class Hsp90 inhibitor 17-AAG entered into Phase I clinical trials in 1999. There are now 13 Hsp90 inhibitors in clinical trial, representing multiple drug classes, and hundreds of patients have been treated in adult oncology and pediatric oncology trials. This review will provide an overview of the clinical trial results thus far. In addition, pivotal issues in further development of Hsp90 inhibitors as anticancer drugs will be discussed.
Keywords: Hsp90 inhibitors, targeted therapy, clinical trial
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Big Data in Biomedicine: Integrating Bioinformatics and Clinical Databases
The rapid advancement of big data technologies is transforming biomedicine by integrating bioinformatics and clinical databases to drive precision medicine and innovative healthcare solutions. This thematic issue explores the intersection of computational biology, machine learning, and biomedical informatics, highlighting how large-scale data analysis enhances disease diagnosis, biomarker discovery, and personalized ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Zebrafish Models for Experimental Pharmacology: A Handbook
Mucosal Vaccine Delivery Systems: The Future of Immunization (Part 1)
Bioactive Compounds Targeting Neurodegenerative Diseases
Anthraquinones: Bioactive Multifaceted Therapeutic Agents
Therapeutic Plants: Recent Advances in the Use of Herbs as Alternative Medications
Quality Assurance of Ethno-Herbals: Cultivating Confidence in Alternative Medicine
Traditional Medicine in North East Africa: Research on Traditional Healer Preparations and Herbs
Andrographolide and its Analogs: Botanical Sources, Phytochemistry, Pharmacology, and Biotechnology
Metabolites of Medicinal Plants: Insightful Approaches
Herbs for Disease Prevention and Treatment
95
